Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

UBS Financial Downgrades Adeza Biomedical


UBS Financial downgrades womens' health products company Adeza Biomedical (ADZA) to neutral from buy.

Analyst Benner Ulrich says shares are up nearly 33% since the company posted first-quarter results, are trading at 21 times his 2007 earnings per share estimate, about in line with a comparable group. He believes upside to estimates are necessary for further multiple expansion.

However, based on recent channel chacks, he remains comfortable with his estimates, and hence downgrades Adeza Biomedical on valuation. He sees 38 cents 2005 earnings per share, and 67 cents 2006 earnings per share, based largely on continued penetration of symptomatic market.

However, Ulrich still thinks conversion of the high-risk market will take time, which is necessary for an upside to his numbers.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus